TP53 and ovarian cancer: However, in P53 (wild type) ovarian cancer cells, the p53 activator RITA can increase the sensitivity of resistant cells to ferroptosis, enhancing the effect of ferroptosis (36).PARP inhibitors, in addition to their therapeutic effects on BRCA mutant ovarian cancer cells, have also been combined with ferroptosis inducers or critical factors to enhance the sensitivity of mutant ovary cancer to ferroptosis.